Vernalis, PLC: Vernalis Collaborates with Unison to Discover Drugs for "Undruggable" Bacterial Target

Vernalis Research formed a research collaboration with Unison Medicines to design small molecules for an undisclosed, hard-to-target bacterial site. Vernalis is a Cambridge UK structure-based drug discovery company that was acquired by Chengdu HitGen in 2020. Unison, a Cambridge, MA startup, develops novel drugs for drug resistant infections. Vernalis will use its drug discovery technology to find small molecules for the Unison target, which has previously been considered undruggable. Unison will finance Vernalis' work and be responsible for paying milestones and royalties on any revenues. Vernalis contributed to Unison's first financing round. More details....Stock Symbol: (SHA: 688222)Share this with colleagues: